Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop.
Garcia JM, Dunne RF, Santiago K, Martin L, Birnbaum MJ, Crawford J, Hendifar AE, Kochanczyk M, Moravek C, Piccinin D, Picozzi V, Roeland EJ, Selig WKD, Zimmers TA. Garcia JM, et al. Among authors: selig wkd. J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):1418-1425. doi: 10.1002/jcsm.12910. Epub 2022 Feb 26. J Cachexia Sarcopenia Muscle. 2022. PMID: 35218313 Free PMC article. No abstract available.
Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group.
Forde PM, Bonomi P, Shaw A, Blumenthal GM, Ferris A, Patel C, Melemed A, Basu Roy U, Ramamoorthy A, Liu Q, Burns T, Gainor JF, Lovly C, Piotrowska Z, Lehman J, Selig W. Forde PM, et al. Clin Lung Cancer. 2020 Jul;21(4):295-307. doi: 10.1016/j.cllc.2020.02.008. Epub 2020 Feb 26. Clin Lung Cancer. 2020. PMID: 32201247
The promise of Immuno-oncology: implications for defining the value of cancer treatment.
Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T 2nd, Campbell JD, Allen J, Ferris AE, Schilsky RL, Danielson D, Lichtenfeld JL, House L, Selig WKD. Kaufman HL, et al. Among authors: selig wkd. J Immunother Cancer. 2019 May 17;7(1):129. doi: 10.1186/s40425-019-0594-0. J Immunother Cancer. 2019. PMID: 31101066 Free PMC article.
Developing standards for breakthrough therapy designation in oncology.
Horning SJ, Haber DA, Selig WK, Ivy SP, Roberts SA, Allen JD, Sigal EV, Sawyers CL. Horning SJ, et al. Clin Cancer Res. 2013 Aug 15;19(16):4297-304. doi: 10.1158/1078-0432.CCR-13-0523. Epub 2013 May 29. Clin Cancer Res. 2013. PMID: 23719260 Free PMC article.
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors.
Ellingson BM, Gerstner ER, Lassman AB, Chung C, Colman H, Cole PE, Leung D, Allen JE, Ahluwalia MS, Boxerman J, Brown M, Goldin J, Nduom E, Hassan I, Gilbert MR, Mellinghoff IK, Weller M, Chang S, Arons D, Meehan C, Selig W, Tanner K, Alfred Yung WK, van den Bent M, Wen PY, Cloughesy TF. Ellingson BM, et al. Neuro Oncol. 2022 Aug 1;24(8):1219-1229. doi: 10.1093/neuonc/noac086. Neuro Oncol. 2022. PMID: 35380705 Free PMC article.
18 results